# NEWSLETTER

**Volume 1, DECMBER 2020**

## ANNOUNCEMENT

- We are pleased to announce that National Cancer Grid (NCG) has approved HCC leukemia registry study project for funding.
- Next webinar on 16th January,2021.

## WE WELCOME ON BOARD NEW DATA ENTRY OPERATORS WHO ARE PLACED AT VARIOUS INSTITUTES

- Arnav Bordoli placed at Department of Clinical Hematology, Gauhati Medical College and Hospital Guwahati
- Ankit Tiwari placed at Department of Hematology at Army Hospital R& R, New Delhi
- Rajesh R placed at Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry
- Abhishek Sood placed at Department of Clinical Hematology- Oncology and Stem Cell Transplantation at Dayanand Medical College and Hospital, Ludhiana
- Mrs.Bommi.K placed at Department of Hematology, Christian Medical College, Vellore
- Aakriti Kapoor Kalra placed at Department of Internal Medicine, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh
- Saranya Bhaskar placed at Department of Clinical Hematology and Medical Oncology of Malabar Cancer Centre (MCC), Kerala

## HCC IS DEEPLY GRATEFUL TO ITS INDIVIDUAL & CORPORATE SUPPORTERS FOR THEIR GENEROSITY

# CLINICAL TRIALS

## Trial 1

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study

Primary Objective(s):

- To validate the Induction Mortality Score developed by HCC in a multicentre prospective cohort of patients with AML receiving induction therapy
- To develop an online calculator for induction mortality score in AML

Secondary Objective(s):

- To study the association of Induction Mortality score model with overall survival (OS)
- To study the association of Induction Mortality score model with event free survival (EFS)

Duration of study: 4 years
Date of Study commencement: 1stJuly, 2020
No of Centres participating in this study : 17
CTRI Registration No: CTRI/2020/07/026450

## Trial 2

Study Title: Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia – A multi-center phase II single arm study

Primary Objective

- To evaluate the 12-month molecular response rate (Bcr-Abl <1%) of generic low dose dasatinib in newly diagnosed patients with chronic phase chronic myeloid leukemia

Secondary Objectives(s):

- To assess the time to molecular response (Bcr-Abl <1% and <0.1%)
- To assess the depth of response at defined time -points
- To assess adverse drug reactions in the study population
- To evaluate 1 year event-free survival and overall survival
- To assess any treatment failure or resistance to low dose dasatinib

Duration of Study: 2 years
Date of Study commencement: October 2020
No of Centres participating in this study: 12
CTRI Registration No: CTRI/2020/10/028317

# COVID-19 HEMATOLOGICAL CANCERS REGISTRY OF INDIA (CHCRI)

Study Design: Observational [Patient Registry]
Estimated Enrollment : 750 participants
Observational Model: Case-Only
Time Perspective: Prospective and Retrospect
Duration: 6 Months
Actual Study Start Date : 1st November, 2020

# WEBINAR SERIES
# APRIL –DECEMBER 2020

| DATE | TOPIC | SPEAKER |
|---|---|---|
| 24-04-2020 | MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES IN THE COVID ERA | DR ELIAS JABBOUR<br>DR NAVAL G DAVER<br>DR NITIN JAIN<br>DR RANJANA H ADVANI<br>DR SUNDAR JAGANNATH |
| 22-05-2020 | CURRENT EVIDENCE IN MANAGEMENT OF CLL &FUTURE DIRECTION | DR NITIN JAIN |
| 08-08-2020 | OVERVIEW OF CYTOMORPHOLOGY IN HEMATOLOGICAL MALIGNANCIES | BRIG DR TATHAGATA CHATTERJEE<br>COL (DR) S VENKATESAN |
| 29-08-2020 | IMMUNOPHENOTYPING: BASIC INTERPRETAION FOR A CLINICIAN | DR PRASHANT TEMBHARE |
| 12-09-2020 | WHAT CAN OUR CHROMOSOMES TELL US? RELEVANCE OF CYTOGENETIC ASSESSMENT IN HEMATOLOGICAL MALIGNANCIES. | DR NANCY BERLY JANET A |
| 26-09-2020 | A PRIMER ON MOLECULAR TESTING IN HAEMATOLOGY<br>MRD IN AML | DR MAHADAVI MADDALI<br>DR NIKHIL PATKAR |
| 24-10-2020 | HOW TO EVALUATE AND INTERPRET FLOW CYTOMERY BASED MRD | DR PRASHANT TEMBHARE |
| 13-11-2020 | LEVERAGING T-CELL ENGAGING IMMUNOTHERAPY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA | DR ELIAS JABBOUR<br>DR HAGOP M KANTARJIAN<br>DR NIKITA MEHRA<br>DR PRASANTH GANESAN |
| 12-12-2020 | A BRAINSTORMING SESSION TO DISCUSS DATA FROM ASH 2020 | EXPERT HEMATO-ONCOLOGISTS FROM HCC CENTERS |
| 19-12-2020 | CHRONIC LYMPHOCYTIC LEUKEMIA | DR NITIN JAIN<br>PROF RITU GUPTA<br>DR PANKAJ MALHOTRA |

# A GLIMPSE OF ASH 2020



















**BECOME A MEMBER TO ACCESS WEBINAR RECORDING**